NIH offers five-year, milestone-driven awards to develop and validate technologies for studying senescent cell diversity and its effects on aging and disease; clinical trials are not allowed.
NIH supports Cellular Senescence Network centers to discover and validate cellular senescence signatures and biomarkers and study their roles in health and disease; clinical trials are not allowed.
NIH funding supports a Stage 2 Cellular Senescence Network center to coordinate, integrate, and share data, maintain data infrastructure, and organize consortium outreach; clinical trials are not allowed.
The NCI plans to fund research projects using systems-level approaches to study metastasis within its Metastasis Research Network, with applications expected in Fall 2025.
NIH funds multisite trials and observational studies using clinical research networks for infants, children, women, pregnant and lactating women, and people with disabilities through milestone-based phases.
This grant supports combined Phase 1/2a clinical trials testing new drugs (excluding amyloid/tau targets) for Alzheimer's, using a milestone-driven approach.